A simple and robust clinical manufacturing process for the ex-vivo expansion of autologous T cells genetically engineered to express an anti-BCMA chimeric antigen receptor (CAR) for the treatment of multiple myeloma
Crossref DOI link: https://doi.org/10.1186/2051-1426-3-S2-P117
Published Online: 2015-11-04
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ladd, Alden
Lilley, Graham
Li, Mingli
Cossette, Dan
Hopkins, Gregory W
Maier, Dawn
Paglia, Michael
Morgan, Richard A
Article History
First Online: 4 November 2015